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Background: The role of tumor suppressor gene RASSF1A in the esophageal and gastric cardia carcinogenesis is
still inconclusive. In this study, the polymorphism, promoter methylation and gene expression of RASSF1A were
characterized in esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA).
Methods: We firstly analyzed the prevalence of RASSF1A A133S in a total of 228 cancer patients with ESCC (n=112)
and GCA (n=116) and 235 normal controls by polymerase chain reaction (PCR) and restriction enzyme-digestion
assay. Then, the promoter methylation status of the RASSF1A in ESCC (n=143), GCA (n=92) and corresponding
adjacent normal tissues were further investigated using methylation-specific PCR (MSP) approach. Finally, the
RASSF1A protein expression were determined in ESCC (n=27), GCA (n=24) and the matched adjacent normal
tissues by immunohistochemical method.
Results: The frequency of 133Ala/Se and Ser/Ser genotype was significantly higher in GCA patients than in normal
controls (19.0% vs. 10.2%, P=0.02). Compared with Ala/Ala genotype, Ala/Se and Ser/Ser genotype significantly
increased susceptibility to GCA (OR=2.06, 95% CI=1.09–3.97). However, this polymorphism had no association with
ESCC (P=0.69). The promoter methylation of RASSF1A gene was significantly increased the risk to both ESCC
(OR=5.90, 95% CI=2.78–12.52) and GCA (OR=7.50, 95% CI= 2.78–20.23). Promoter methylation of RASSF1A gene in
ESCC was also associated with age and cancer cell differentiation (for age: OR=3.11, 95% CI=1.10–8.73; for
differentiation: OR=0.29, 95% CI=0.12–0.69). RASSF1A positive expression was significantly decreased the risk of GCA
(OR=0.16, 95% CI=0.03–0.83). In contrast, there was no statistical significance between RASSF1A positive expression
and ESCC. The expression of RASSF1A protein trend to be positively related with older GCA patients (OR=16.20,
95% CI=1.57–167.74).
(Continued on next page)* Correspondence: ldwang2007@126.com
1Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated
Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China
Full list of author information is available at the end of the article
© 2013 Zhou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Zhou et al. BMC Cancer 2013, 13:259 Page 2 of 10
http://www.biomedcentral.com/1471-2407/13/259(Continued from previous page)
Conclusions: The present findings suggest that alterations of RASSF1A may play an important role in gastric cardia
carcinogenesis in terms of polymorphism, promoter hypermethylation and protein expression. Whereas, RASSF1A
hypermethylation may probably also be involved in esophageal squamous cell carcinogenesis.
Keywords: Esophageal squamous cell carcinoma, Gastric cardia adenocarcinoma, A133S in RASSF1A, Polymorphism,
Methylation, Protein expressionBackground
Esophageal squamous cell carcinoma (ESCC) remains the
main predominant histological type of esophageal cancer
and the leading cause of cancer-related deaths in China
[1,2]. ESCC has a striking geographic distribution in China,
with higher prevalence in some areas of China, especially
in Taihang Mountain areas of Henan, Hebei and Shanxi
provinces [3], where nutritional deficiencies, intake of pick-
led vegetables, nitrosamine-rich or mycotoxin-contaminated
foods and low socioeconomic status are likely to contribute
to ESCC [4]. Also, in these high-risk areas there is a strong
tendency toward familial aggregation of ESCC [5], suggesting
that genetic susceptibility, in combination with exposure
to environmental risk factors, contributes to the high rates
of ESCC in these areas [6]. ESCC has been generally re-
cognized as a multi-stage progression process, in which
multiple genetic and epigenetic alterations may be in-
volved. Recent genome-wide association study (GWAS)
for ESCC has indicated that the tumor suppressor gene
of Ras association domain family 1A gene (RASSF1A)
may be associated with high risk to ESCC [6]. RASSF1A
locates at 3p21.3 and participates in regulating cell cycle,
apoptosis, microtubule stability and other physiological ac-
tivities [7,8]. Accumulated evidences have indicated the
possible crucial role of RASSF1A methylation on esopha-
geal carcinogenesis in Chinese population, the methylation
rates varied from 14.9% [9] in Beijing with a low incidence
for ESCC, to 48.5% [10] in Hangzhou with a higher inci-
dence for ESCC, indicating the disparity of RASSF1A
methylation with different environment background. The
single nucleotide polymorphism (SNP) Ala133Ser (A133S)
in RASSF1A has been reported to be involved in the lung
and breast cancer [11,12]. Linzhou city (formerly Linxian)
in Henan province has been well documented as the
highest incidence area for ESCC in China [2,3]. However,
the effects of RASSF1A polymorphism and methylation on
esophageal carcinogenesis have not been well characterized
in the population from this highest incidence area in China.
Gastric cardia adenocarcinoma (GCA), with its epicenter
located between 1 cm proximal and 2 cm distal of the
esophago-gastric junction [13], is another common cancer
in China, which bears many similarities to ESCC in terms of
concurrent geographic distribution and environmental risk
factors [6,14]. It is reasonable to clarify the molecular pro-
file of ESCC and GCA, which would be helpful to identifymolecular biomarkers for high risk subject screening and
early detection for these two diseases. Thus, the present
study was undertaken to determine the effect of RASSF1A
polymorphism, promoter methylation status and protein
expression on esophageal and gastric cardia carcinogenesis
in patients from the high incidence area for both ESCC and
GCA in Linzhou city, Henan province, northern China.Methods
Study population
A total of 259 patients were recruited in this study, includ-
ing 143 ESCC (82 males with a mean age (average±standard
deviation) of 57±10 years and 61 females with a mean age
of 59±10 years) and 116 GCA (70 males with a mean age of
55±10 years and 46 females with a mean age of 60±10
years). All the patients were from Linzhou, the high inci-
dence area for both ESCC and GCA. All the patients were
performed surgical treatment, without chemotherapy and/
or radiotherapy before the surgery. In addition, 235 normal
control subjects were enrolled in this study, including 115
males with a mean age of 58±9 years and 100 females with
a mean age of 59±9 years. All the subjects were performed
biopsy under endoscopy to exclude upper gastrointes-
tinal tumor and questionnaires to exclude tumor history
and tumor family history. All these subjects were from
endoscopy screening for early cancer detection on
symptom-free subjects in Linzhou city. Informed con-
sents were obtained from all participants according to
Zhengzhou University and Linzhou Esophageal Cancer
Hospital Review Boards.Histopathological examinations
Histopathlogical examinations and TNM staging were
performed by two pathologists (X. M. Li and J. L. Li)
based on the UICC criteria in 2002 [15]. In brief, all the
esophageal cancers were confirmed as squamous cell
carcinoma and gastric cardia cancers as adenocarcin-
oma. The gross morphological types for ESCC and GCA
were classified as medullary, fungating, ulcerating, constric-
tion and intraluminal in ESCC; and protruding, ulcerating
and infiltrating in GCA. The differentiation for both ESCC
and GCA was classified as high, middle and low grades.
Lymph node metastasis was recorded as negative and
positive, if any.
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tissue collection
Five ml peripheral blood samples for each patient and
each normal subject, and surgically resected ESCC and
GCA tissue samples were collected sequentially at
Linzhou Esophageal Cancer Hospital and endoscopy
screening from 2000 to 2008. The blood samples were
stored at −40°C until use. The tumor tissues and
matched normal tissues were collected after surgery, half
of the surgically resected sample was formalin-fixed,
paraffin-embedded and another half stored at −80°C.
The criteria for matched samples are defined as that the
tumor tissues and the normal tissues are from the same
patients, and the matched normal tissues are taken at
the surgically resected margin excluding the infiltration
of carcinoma cells. Finally, a total of 463 blood samples
were recruited for polymorphism detection, including
112 ESCC, 116 GCA and 235 normal controls. Another
group of surgically resected esophageal and gastric car-
dia cancer and matched normal tissue specimens were
recruited for the RASSF1A methylation detection. A
total of 143 ESCC tissue specimens and 92 GCA tissue
specimens were used for methylation detection, inclu-
ding 62 matched esophageal cancer and normal tissues,
and 30 matched gastric cardia cancer and normal tis-
sues. For further determination of RASSF1A protein ex-
pression, 27 ESCC tissue specimens with 27 matched
normal esophageal tissue specimens and 24 GCA tissue
specimens with 24 matched normal gastric cardia tissue
specimens were recruited from 143 ESCC and 92 GCA,
which had been used for RASSF1A methylation detec-
tion. This study was reviewed and approved by the Insti-
tute Research Ethics Committee of the Zhengzhou
University and informed consents were obtained from
all participants before their blood and tissue samples
were used.
DNA extraction
For polymorphism detection, genomic DNA from per-
ipheral leucocytes was extracted by phenol/chloroform
extraction method, dissolved in TE balanced solution,
and then stored at −80°C for next procedure.
For methylation profiles and protein expression exa-
mination, the paraffin-embedded tissue blocks of tumor
tissue (both ESCC and GCA) and corresponding adja-
cent normal tissue were sectioned for hematoxylin and
eosin staining with the purpose of identifying patho-
logical diagnose reviewed by pathologist. Regions with
neoplastic compositions of 80% or greater were marked
as tumor tissue under optical microscope. Depending on
the size of the tissue, 15 to 20 consecutive 10 μm sec-
tions of each block were manually microdissected using
a needle and collected into 1.5 ml microtubes for DNA
extraction. The tissue DNA extraction was carried outusing the Puregen Genomic DNA purification kit
(Gentra Systems, MN, USA) according to the manufac-
turer’s protocols. The DNA from tissue was stored at
−80°C for next procedure.
Genotyping
The nest PCR was performed in a 25 μl reaction
containing 1 μl for genome DNA, 10mmol/L dNTP, 10X
buffer solution, 5pmol up and down primer respectively
and 1U Ex Taq DNA polymerase. All the reagents in-
volved were purchased from TaKaRa, Beijing city, China.
The sequences of both outside and inside primers were
designed based on the reference sequence (chr3-
50342222-50353371) using Primer 3.0 as follows: outside
primer: forward 5′ATG ATT CTG TCT TTC CCT TAT
CCA and reverse 5′ACC AAA CCT TGA TAA TAG
GTT CCA; inner primer: forward 5′AAG GCA GTC
AGT TTC CAA AGA CT and reverse 5′ATG AAG
AGG TTG CTG TTG ATC TG. The amplification was
conducted on the GennAmp RCR system 9700 gene
amplifier (ABI, California, USA) under the following
thermo-cycler conditions: pre-degeneration at 94 °C for
5 min; followed by 16 cycles at 94°C for 30 sec, at 64°C
(−0.3°C/circulation) 30 sec and at 72°C for 30 sec; 20X
(94°C for 30 sec, 56°C for 40 sec and 72°C for 30 sec);
then, extension at 72°C for 10 min, and finally stored at
4°C. The final product of nest PCR was 194 bp. 10 μl
PCR product was digested with restriction enzymes AluI
(TaKaRa, Beijing city, China.) incubated at 37°C over-
night. The digestion product was detected on a 3%
agarose gel stained with ethidium bromide under UV
illumination.
The 133rd amino acid which was encoded by the exon
3 of RASSF1A is GCT (Ala) or TCT (Ser), if the locus
was allele G, this read was restriction site of AluI. Be-
cause of that, Ala/Ala genotype was two bands of 136 bp
and 58 bp, Ala/Ser genotype was three bands of 194 bp,
136 bp and 58 bp, Ser/Ser genotype was just one band
of 194 bp (Figure 1). For quality assurance, both Ala/Ser
and Ser/Ser genotypes were genotyped more than twice,
moreover, all of the Ser/Ser, portion of Ala/Ser and
some Ala/Ala genotypes which randomly selected were
sequenced to testify the genotyping results. The se-
quencing analysis was conducted using ABI3730XL Se-
quencers (ABI, California, USA) at Beijing Sunbiotech
Co., Ltd. (Beijing, China).
Bisulfite treatment and methylation specific PCR (MSP)
Genomic DNA (1μg) was treated with sodium bisulfite
modification in order to converting unmethylated cyto-
sines to uracils using the CpGenome™ DNA Modifica-
tion Kit (S7820) (Chemicon, California, USA) according
to manufacturer’s protocol. The modified DNA was
purified by using a Wizard DNA Clean-Up System
Figure 1 The genotying results of the RASSF1A SNP at codon
133. PCR analysis of the RASSF1A SNP at codon 133. Land 1: Marker;
Land 2: Ser/Sergenotype; Land 3 and 4: Ala/Ala genotypes; Land
5:Ala/Ser genotype.
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facturer’s protocol.
The bisulfite-modified DNA was subjected to methyla-
tion specific polymerase chain reaction (MSP) as de-
scribed previously [16]. Primers targeting promoter
region of RASSF1A were as follows: The specific primers
for methylated sequences (forward 5′- GTG TTA ACG
CGT TGC GTA TC and reverse 5′- AAC CCC GCG
AAC TAA AAA CGA) and for unmethylated sequences
(forward 5′- TTT GGT TGG AGT GTG TTA ATG TG
and reverse 5′- CAA ACC CCA CAA ACT AAA AAC
AA), which generates PCR products of 93 and 105 bp,
respectively. The total 25 ml of PCR mix contained
50-100ng bisulfite-modified DNA, 10X PCR buffer
(Mg2+ Plus), 3.0 μl; 2.5 mM dNTPs, 3.0 μl; 10 μM of
each primer, 2.0 μl; and 0.5 U TaqHS DNA polymerase,
2.5 μl (TaKaRa, Dalian city, China). The amplification
was conducted on the Tgradient RCR system (Biometra,
Goettingen, German) under the following thermo-cycler
conditions: pre-degeneration at 95°C for 15 min; followed
by 40 cycles at 95°C for 55 sec, at 65°C for 55 sec and at
72°C for 1 min; 20X (94°C for 30 sec, 56°C for 40 secFigure 2 MSP analysis of RASSF1A gene in ESCC and GCA tissue. Repr
was the results of three GCA tissues (T4, T5, and T6). Lane M: indicates the
unmethylated genes. T1 and T4 were fully hypermethylation which reveale
unmethylation, having only unmethylated band of 105 bp; T2 and T5 were
unmethylated band.and 72°C for 30 sec; then, extension at 72°C for 10 min.
The placenta tissue DNA which was treated with Sss
I methyltransferase (TaKaRa, Dalian city, China) was
used as positive control for methylation, while taking
the placenta tissue DNA which was not digested by
Sss I methyltransferase as positive control for
unmethylation; Distilled water was used as negative con-
trol for PCR. Both of the positive and negative controls
were deal with in the same procedures. Six μl of PCR
products were separated on 10% polyacrylamide gel. The
gel was then stained with ethidium bromide, and
visualized under UV illumination. Methylated samples
were defined as the presence of methylated PCR products
in those samples (Figure 2).Immunohistochemical analysis
Partial of the samples which were inspected by MSP,
about 27 ESCC and 24 GCA, as well as corresponding adja-
cent normal epithelial tissues were subjected to investigate
RASSF1A protein expression by immunohislochemical
staining. Immunohislochemical analysis was performed
using the avidin-biotin-peroxidase complex method as pre-
viously described [17]. The rat anti-human monoclonal
RASSF1A antibody (eBioscience corporation, San Diego,
USA) was used at 1:500 dilution. Intense nuclear or cyto-
plasm staining was the criterion for a “positive” reaction.
We applied the criteria established by our laboratory
previously [17] to describe the types of positive result as
follows: “scattered”, in which only some isolated positive
cells were identified; “papillary”, where immunostain-
positive cells were identified only in the papillary area;
“focal”, where wide clusters of positive cells were seen
in some areas of the epithelia; and “diffuse”, in which the
sheets of positive cells were found throughout most areas
of the lesions. Immunohistochemical labeling was esti-
mated in an outcome-blinded model by two pathologists
on a compound microscope.esentative MSP results of three ESCC tissues (A, T1, T2, and T3) and (B)
presence of methylated genes; Lane U: indicates the presence of
d 93 bp band (M) with hypermethylated primers; T3 and T6 were
Hemi-methylation with both hypermethylated band and
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Consistency with Hardy–Weinberg equilibrium (HWE)
of the genotypes of the ESCC/GCA and control groups
was established by Chi-squared tests. The association of
Genotype and diseases were assessed using logistic re-
gression and expressed as odds ratios with 95% confi-
dence intervals. For RASSF1A gene methylation and
protein expression, the correlations with clinic charac-
teristics in ESCC and GCA tissues were evaluated using
multiple univariate logistic-regressions. The statistical
analyzes were carried out with SPSS 17.0 software pack-
age. All tests were two tailed. P < 0.05 was considered
statistically significant.
Results
Frequency of RASSF1A A133S in ESCC and GCA patients
All the 235 control, 112 ESCC and 116 GCA samples
were analyzed for the presence of A133S (Table 1).
There were no departures from the HWE in the geno-
typing results of ESCC, GCA or control samples
(P=0.83). The homozygous or heterozygous for A133S
were accounted for 11.6% (13/112) in the ESCC and
10.2% (24/235) in control subjects. Though the frequen-
cies of A133S in ESCC was a little higher than in con-
trols, Ala/Se and Ser/Ser genotype did not increase the
risk of ESCC compared with Ala/Ala genotype (11.2%
vs. 10.2%, P=0.69; OR=1.15; 95% CI=0.51–2.44).
Intriguingly, in GCA, there was a significant difference
of the frequency of the RASSF1A A133S T allele com-
pared with the controls (19.0% vs. 10.2%). The individ-
uals carrying A133S (Ser/Ser) genotype had a much
higher susceptibility to GCA compared with people
carrying Ala/Ala genotype (P=0.04, OR=9.01, 95%
CI= 0.99–83.31). In addition, compared with Ala/Ala
genotype, Ala/Se and Ser/Ser genotype also significantly
increased susceptibility to GCA (P=0.02, OR=2.06,
95% CI=1.09–3.971).
The promoter methylation of RASSF1A in ESCC and GCA
patients
The promoter methylation of RASSF1A in ESCC tissue
was 3.4-fold higher than in adjacent normal mucosa (76/
143, 53% vs. 10/62, 16%, P < 0.001). The promoterTable 1 The genotypings of A133S in RASSF1A gene on ESCC
Genotypings* Control ESCC
n (%) n (%) P OR
Ala/Ala 211 (89.8) 99 (88.4)
Ala/Ser 23 (9.7) 11 (9.8) 0.96 1.02
Ser/Ser 1 (0.4) 2 (1.8) 0.24 4.26
Ala/Se and Ser/Ser 24 (10.2) 13 (11.6) 0.69 1.15
*: Ala/Ala: homozygous for wild-type codon 133, Ala/Ser: heterozygote for codon 13hypermethylation of RASSF1A gene significantly in-
creased almost 6-fold higher the risk to ESCC develop-
ment (OR=5.90, 95% CI=2.78–12.52). Interestingly, the
similar results were observed in GCA, the promoter
hypermethylation of RASSF1A gene significantly in-
creased almost 7.5-fold higher the risk to GCA develop-
ment (65% in GCA vs. 20% in adjacent normal mucosa,
OR=7.50, 95% CI=2.78–20.23) (Table 2 and Figure 2).
Furthermore, the promoter methylation of RASSF1A
in ESCC patients with the age group from 50–60 years
old had a significantly higher risk to ESCC than in those
with the age less than 50 years old (OR=3.11, 95%
CI=1.10–8.73) (Table 3). The ESCC with moderate dif-
ferentiation had a lower frequency of RASSF1A methyla-
tion than in those with higher differentiation (OR=0.28,
95% CI=0.12–0.69) (Table 3). However, multivariate ana-
lysis did not show did not show any significant associ-
ation for RASSF1A promoter methylation and gender,
gross pathologic classification, infiltration degree, lymph
node metastasis and clinical stages both in ESCC and
GCA.Correlations of the RASSF1A protein immunoreactivity
and hypermethylation of RASSF1A gene
In ESCC, all the 7 cases with RASSF1A promoter
methylation-positive tissues (7/10, 70%), showed com-
pletely lack of immunoreactivity for RASSF1A, similar
results were observed for the matched adjacent normal
tissue. Interestingly, of the 17 cases with RASSF1A pro-
moter methylation-negative tissues, 11 cases showed
positive immunoreactivity for RASSF1A (11/17, 65%).
RASSF1A positive staining was negatively associated
with RASSF1A promoter methylation in the ESCC
(P=0.09, Fisher’s exact test) (Table 3).
In GCA, all the 10 cases with RASSF1A promoter
methylation-positive tissues, RASSF1A protein expres-
sion was not detected (Table 3). But, of the 14 cases with
RASSF1A promoter methylation-negative tissues, 9 cases
showed RASSF1A positive expression (64%). There was
a significant correlation between RASSF1A promoter
hypermethylation and loss of RASSF1A protein expres-
sion in GCA (P=0.001, Fisher’s exact test).and GCA patients and normal controls
GCA
(95%CI) n (%) P OR (95%CI)
94 (81.0)
(0.48–2.17) 18 (15.5) 0.09 1.76 (0.91–3.41)
(0.38–47.02) 4 (3.5) 0.04 9.01 (0.99–83.31)
(0.51–2.44) 22 (19.0) 0.02 2.06 (1.09–3.97)
3, Ser/Ser: homozygous for codon A133S.
Table 2 The profiles of RASSF1A promoter hypermethylation in ESCC and GCA tissues and in normal tissues adjacent
to the corresponding ESCC and GCA
Tissues# N Methylated Unmethylated P OR (95%CI)
n (%) n (%)
ESCC 143 76 (53) 67 (47) <0.001 5.90 (2.78–12.52)
ENOR 62 10 (16) 52 (84)
GCA 92 60 (65) 32 (35) <0.001 7.50 (2.78–20.23)
GNOR 30 6 (20) 24 (80)
#: ESCC: esophageal squamous cell carcinoma, ENOR: esophageal normal epithelial tissue, GCA: gastric cardia adenocarcinoma, GNOR: gastric cardia normal
epithelial tissue.
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The positive expression of the RASSF1A protein was
located in cell nucleus and cytoplasm. The positive
immunostaining rate for RASSF1A in ESCC tissue
was slightly lower than in adjacent normal tissues
(17/27, 63% vs. 21/27, 78%). But, the difference was
not significant (P=0.24) (Table 4). No association was
found for RASSF1A protein expression and gender,
age, cancer cell differentiation, infiltration degree and
lymph node metastasis or clinical stages in ESCC
(Table 5).
However, RASSF1A protein positive immunostaining
rate in GCA tissues was much lower than in adjacent
normal gastric cardia tissue (14/24, 58% vs. 22/24, 92%,
P=0.02) (Table 4). Furthermore, RASSF1A expression in
GCA patients over 70 years old was significantly higher
than in those under 40 years old (58% vs. 42%;
OR=16.20, 95% CI=1.57–167.74) (Table 5). No associ-
ation was found for RASSF1A protein expression and
gender, cancer cell differentiation, infiltration degree
and lymph node metastasis in GCA (Table 5).
Discussion
In the present study, we firstly investigated the RASSF1A
A133S polymorphism and the risk to ESCC and GCA
development on the patients from Linzhou, the high in-
cidence area for both ESCC and GCA. Our results dem-
onstrated that the existence of polymorphic allele of
RASSF1A might participate in gastric cardia carcinoge-
nesis. The carriers with Ser/Ser genotype (the homozygote
for codon RASSF1A A133S) and with mutated T allele
genotype (Ala/Ser+Ser/Ser genotype) could have 9-fold
(OR=9.01, 95% CI=0.99–83.31) and 2-fold (OR=2.06, 95%
CI=1.09–3.97) higher risk to GCA, respectively. In con-
trast, the presence of SNP A133S in RASSF1A seems to be
not involved in esophageal squamous cell carcinogenesis
(P=0.69). Histopathologically, the predominant type for
gastric cardia is adenocarcinoma, but the predominant
type for esophageal cancer is squmous cell carcinoma in
Chinese population, which may partially explain the gen-
etic risk difference observed in the present study. It has
been reported that single nucleotide polymorphism atcodon 133 of the RASSF1 gene is preferentially associated
with human lung adenocarcinoma risk, but not for human
lung squamous cell carcinoma [11].
In this study, we also investigated RASSF1A promoter
methylation in ESCC and GCA. Aberrant RASSF1A pro-
moter methylation was found in 53% (76/143) of Chin-
ese ESCC, significantly increased 5.9-fold higher the risk
to ESCC (OR=5.90, 95% CI=2.78–12.52). It was appar-
ently higher than in Korean ESCC (14%, 7/50) [18] and
Japanese ESCC (24%, 13/55) [19]. Interestingly, another
two reports also show higher frequency of RASSF1A
promoter methylation in Chinese ESCC from Hong
Kong (34%, 22/64) [20] and Hangzhou (48.5%, 32/66)
[10], the high incidence area for ESCC in China. It is
noteworthy that Chinese ESCC from low incidence area
seems to have low frequency of RASSF1A promoter
methylation (14.9% 22/64) [9]. Obviously, the RASSF1A
promoter methylation may be interfered by genetic and
environmental factors from different population. In this
study, we found that the prevalence of RASSF1A pro-
moter methylation and the risk to ESCC in ESCC pa-
tients with the age of more than 50 years old were
higher than those with less than 50 years old (OR=3.11,
95% CI=1.10–8.73), which further indicate the impact of
environmental factor in terms of exposure time on
RASSF1A promoter methylation.
Of particular interest, we also demonstrated the simi-
lar hypermethylation of RASSF1A in GCA (65%, 60/92),
the promoter hypermethylation of RASSF1A significantly
increased 7.5-fold higher the risk to GCA (OR=7.5, 95%
CI=2.78–20.23), which is very similar as in ESCC. It is
noteworthy that these GCA patients enrolled in our
study were from the same high incidence area as the
ESCC patients, suggesting that there may be similar en-
vironmental carcinogenic factors involved in ESCC and
GCA. GCA seems to occur together with ESCC in
China and bears many similarities in terms of concur-
rent geographic distribution and environmental risk fac-
tors including nutritional deficiencies, low intake of
vegetables and fruit, and low socioeconomic status [14].
Recent GWAS studies have demonstrated the similar
genetic changes for ESCC and GCA in Chinese
Table 3 Distribution of RASSF1A promoter methylation by clinicopathological classifications and protein expression in ESCC and GCA tissues
Classification ESCC (n=143) GCA (n=92)
N Methylated Unmethylated P OR (95%CI) N Methylated Unmethylated P OR (95%CI)
n (%) n (%) n (%) n (%) n (%) n (%)
Gender
Male 82 (57) 43 (52) 39 (48) 58 (63) 37 (64) 21 (36)
Female 61 (43) 33 (54) 28 (46) 0.84 0.94 (0.48–1.82) 34 (37 23 (68) 11 (32) 0.71 0.84 (0.34–2.07)
Age (y)
≤50 25 (17) 13 (52) 12 (48) 21 (23) 16 (76) 5 (24)
50–60 48 (34) 37 (77) 11 (23) 0.03 3.11 (1.10–8.73) 32 (35) 19 (59) 13 (41) 0.21 0.46 (0.13–1.56)
>60 70 (49) 26 (37) 44 (63) 0.20 0.55 (0.22–1.37) 39 (42) 25 (64) 14 (36) 0.34 0.56 (0.17–1.85)
Gross pathologic classificationΦ
1 38 (27) 18 (47) 20 (53) 17 (18) 10 (59) 7 (41)
2 25 (17) 16 (64) 9 (36) 0.58 0.74 (0.25–2.20) 32 (34) 24 (67) 8 (33) 0.25 2.10 (0.60–7.36)
3 29 (20) 19 (66) 10 (34) 0.91 0.92 (0.23–3.77) 33 (36) 21 (64) 12 (36) 0.74 1.23 (0.37–4.06)
4 19 (13) 15 (79) 4 (31) 0.06 0.39 (0.14–1.05) ND ND ND ND ND ND
Unclear 32 (22) 8 (25) 24 (75) 10 (11) 5 (50) 5 (50)
Differentiation classification
High 32 (22) 22 (69) 10 (31) 20 (22) 14 (70) 6 (30)
Middle 70 (49) 27 (39) 43 (61) 0.006 0.28 (0.12–0.69) 31 (34) 22 (71) 9 (29) 0.94 1.05 (0.31–3.59)
Low 34 (24) 26 (76) 8 (24) 0.48 1.48 (0.50–4.39) 41 (45) 24 (59) 17 (41) 0.39 0.61 (0.19–1.89)
Unclear 7 (5) 1 (14) 6 (86) ND ND ND ND ND ND
Tumor stage (T) classification
T1+T2 25 (17) 13 (52) 12 (48) 14 (15) 9 (64) 5 (36)
T3+T4 113 (79) 62 (55) 51 (45) 0.38 1.38 (0.68–2.82) 78 (85) 51 (65) 27 (35) 0.77 1.20 (0.36–4.04)
Unclear 5 (3) 2 (40) 3 (60) ND▲ ND ND ND ND ND
Tumor stage (N) classification
N0 91 (64) 48 (53) 43 (47) 44 (48) 28 (64) 16 (36)
N1 47 (33) 27 (57) 20 (43) 0.60 1.21 (0.60–2.46) 48 (52) 32 (67) 16 (33) 0.76 1.143 (0.48–2.70)

















Table 3 Distribution of RASSF1A promoter methylation by clinicopathological classifications and protein expression in ESCC and GCA tissues (Continued)
Tumor stage (TNM) classification
I+II 91 (64) 47 (52) 44 (48) 47 (51) 30 (64) 17 (36)
III+IV 47 (33) 28 (60) 19 (40) 0.38 1.38 (0.68–2.82) 45 (49) 30 (67) 15 (33) 0.78 1.13 (0.48–2.68)
Unclear 5 (3) 1 (20) 4 (80) ND ND ND ND ND ND
RASSF1A protein
positive 17 (63) 6 (35) 11 (65) 14 (58) 5 (36) 9 (14)
negative 10 (37) 7 (70) 3 (30) 0.09 0.23 (0.04–1.25) 10 (42) 10 (100) 0 (0) 0.001


















Table 4 RASSF1A protein expression in ESCC and GCA
tissues and in normal tissues adjacent to the
corresponding ESCC and GCA
Tissues N Postive Negative P OR (95%CI)
n (%) n (%)
ESCC 27 17 (63) 10 (37 ) 0.24 0.47 (0.13–1.67)
ENOR 23 18 (78) 5 (22)
GCA 24 14 (58) 10 (42) 0.03 0.16 (0.03–0.83)
GNOR 20 18 (90) 2 (10)
#: ESCC: esophageal squamous cell carcinoma, ENOR: esophageal normal
epithelial tissue, GCA: gastric cardia adenocarcinoma, GNOR: gastric cardia
normal epithelial tissue.
Zhou et al. BMC Cancer 2013, 13:259 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/259population [6]. Furthermore, our results is close to the
findings of RASSF1A gene methylation in GCA patients
from Hebei province (58.7%, 54/92) [21], another high in-
cidence area for ESCC and GCA in TaiHang Mountain.
It is noteworthy that, in the present study, we also ob-
served the RASSF1A promoter methylation in the nor-
mal esophageal and gastric cardia epithelial tissue
adjacent to corresponding ESCC and GCA (in ESCC:
13%, 23/143; in GCA: 20%, 19/92). These histological
normal tissue has been exposed to same carcinogenic
factors with tumor tissues. The present results indicate
that RASSF1A promoter methylation may be a promi-






n (%) n (%) n (%)
Gender
Male 18 (67) 10 (56) 8 (44)
Female 9 (33) 7 (78) 2 (22) 0.27 0.36(0
Age(y)
≤40 12 (44) 10 (83) 2 (17)
≥70 15 (56) 7 (47) 8 (53) 0.06 5.71(0.9
Differentiation classification
High+Middle 23 (85) 13 (57) 10 (43)
Low 4 (15) 4 (100) 0 (0) 0.10
Tumor stage (T) classification
T1+T2 6 (22) 4 (67) 2 (33)
T3+T4 21 (78) 13 (62) 8 (38) 0.57 1.88(0.2
Tumor stage (N) classification
N0 20 (74) 13 (65) 7 (35)
N1 7 (26) 4 (57) 3 (43) 0.41 2.18(0.3
Tumor stage (TNM) classification
I+II 20 (74) 12 (60) 8 (40)
III+IV 7 (26) 5 (71) 2 (29) 0.59 1.67(0.2carcinogenesis. Further studies are required to
characterize the RASSF1A promoter methylation in
esophageal and gastric cardia precancerous lesion.
Another interesting finding in this study is that
RASSF1A promoter hypermethylation could significantly
downregulated RASSF1A protein expression both in
ESCC and GCA, further indicating the possible crucial
role of RASSF1A promoter hypermethylation and pro-
tein expression in esophageal and gastric cardia
carcinogenesis.
Finally, considering the obvious impact of environ-
mental factors on DNA methylation, the advantage of
our study is the large sample size with similar lifestyle
background. All the ESCC and GCA patients and con-
trol subjects enrolled in this study were from the same
high incidence area for both ESCC and GCA.
Conclusions
In conclusion, this is the first study to reveal the interac-
tions of RASSF1A polymorphism, promoter methylation
and protein expression on the risk of esophageal and
gastric cardia carcinogenesis. RASSF1A promoter
hypermethylation could significantly increase 6-fold
and 8-fold higher risk to ESCC and GCA develop-
ment, respectively, and induce the inactivation of RASSF1A





n (%) n (%) n (%)
14 (58) 6 (43) 8 (57)
.06–2.22) 10 (42) 8 (80) 2 (20) 0.08 0.19(0.03–1.23)
10 (42) 9 (90) 1 (10)
2–35.48) 14 (58) 5 (36) 9 (64) 0.02 16.20(1.57–167.74)
14 (58) 6 (43) 8 (57)
10 (42) 8 (80) 2 (20) 0.08 0.19(0.03–1.23)
2 (8) 1 (50) 1 (50)
2–15.93) 22 (92) 13 (59) 9 (41) 0.73 0.75(0.15–3.83)
15 (63) 9 (60) 6 (40)
5–13.76) 9 (38) 5 (56) 4 (44) 0.83 0.83(0.16–4.44)
21 (88) 12 (57) 9 (43)
6–10.79) 3 (13) 2 (67) 1 (33) 0.76 1.50(0.12–19.24)
Zhou et al. BMC Cancer 2013, 13:259 Page 10 of 10
http://www.biomedcentral.com/1471-2407/13/259that RASSF1A promoter hypermethylation may play an
important role both in esophageal and gastric cardia car-
cinogenesis. The T allele (Ala/Ser + Ser/Ser genotype) of
RASSF1A A133S could increase the risk to GCA develop-
ment, but not to ESCC. Certainly, further work should be
done to illustrate the mechanism of RASSF1A in the de-
velopment of ESCC and GCA, and ultimately develop
RASSF1A gene as one of the molecular biomarkers for
high-risk subject screening and early detection for ESCC
and GCA in future.
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